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Abstract
Expression of the transmembrane NG2 chondroitin sulphate proteoglycan (CSPG) defines a distinct population
of NG2-glia. NG2-glia serve as a regenerative pool of oligodendrocyte progenitor cells in the adult central
nervous system (CNS), which is important for demyelinating diseases such as multiple sclerosis, and are a major
component of the glial scar that inhibits axon regeneration after CNS injury. In addition, NG2-glia form unique
neuron–glial synapses with unresolved functions. However, to date it has proven difficult to study the
importance of NG2-glia in any of these functions using conventional transgenic NG2 ‘knockout’ mice. To
overcome this, we aimed to determine whether NG2-glia can be targeted using an immunotoxin approach. We
demonstrate that incubation in primary anti-NG2 antibody in combination with secondary saporin-conjugated
antibody selectively kills NG2-expressing cells in vitro. In addition, we provide evidence that the same protocol
induces the loss of NG2-glia without affecting astrocyte or neuronal numbers in cerebellar brain slices from
postnatal mice. This study shows that targeting the NG2 CSPG with immunotoxins is an effective and selective
means for killing NG2-glia, which has important implications for studying the functions of these enigmatic cells
both in the normal CNS, and in demyelination and degeneration.
Key words: glia; immunoablation; immunotoxin; NG2 proteoglycan; oligodendrocyte progenitor cells;
oligodendrocyte precursor cells.
Introduction
The NG2 chondroitin sulphate proteoglycan (CSPG) is
expressed in both the developing and adult central nervous
system (CNS), where it marks a specific population of glial
cells (Butt et al. 2002). A primary function of NG2-glia is to
act as oligodendrocyte progenitor cells (OPCs), generating
oligodendrocytes during development and in the adult (Riv-
ers et al. 2008; Etxeberria et al. 2010). Most significantly,
NG2-glia have been shown to form functional synapses with
neurons in hippocampal, cortical and cerebellar slices (Ber-
gles et al. 2000; Lin et al. 2005; Ge et al. 2006; Kukley et al.
2008; De Biase et al. 2010; Etxeberria et al. 2010; Velez-Fort
et al. 2010), and with nodes of Ranvier in white matter
(Butt et al. 1999; Kukley et al. 2007; Ziskin et al. 2007; Ham-
ilton et al. 2010). In addition, NG2-glia may also perform a
structural function at synapses (Stegmuller et al. 2003). A
key aspect of NG2-glia is that they are highly reactive cells
and respond to most forms of CNS injury by a rapid increase
in proliferation and glial scar formation (Levine et al. 2001;
Tan et al. 2005). Notably, NG2 is considered one of the main
molecules in the glial scar that contributes to the failure of
axon regeneration in the adult CNS (Sandvig et al. 2004;
Tan et al. 2005). Neurotransmission may serve as a regula-
tory mechanism for controlling the developmental progres-
sion of NG2-glia (Etxeberria et al. 2010), and a further
possibility is that it regulates an injury response in NG2-glia
(Hamilton et al. 2010). Hence, regulating NG2-glia has
potential significance in normal brain development and
function, and in demyelination and degeneration.
The functions of NG2-glia are in part directly related to
the properties of the CSPG molecule (Nishiyama et al.
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1996b; Levine et al. 2001; Stallcup, 2002; Stegmuller et al.
2003). However, a line of NG2-null mice has been produced,
and these did not manifest gross phenotypic differences
(Grako et al. 1999). Subsequent studies have indicated
subtle changes in oligodendrocytes, with a reduction in the
numbers and proliferation of OPCs in developing white
matter and a delay in myelination in the NG2 null mouse
(Kucharova & Stallcup, 2010). However, there are no appar-
ent effects on hippocampal neurogenesis (Thallmair et al.
2006), or on axonal regeneration in the CNS and peripheral
nervous system (Hossain-Ibrahim et al. 2007). These genetic
studies did not result in the loss of NG2-glia, and so we
wished to develop a system that specifically ablates these
cells. Immunotoxins have been used successfully for elimi-
nating particular neural populations on the basis of their
expression of specific antigens (Wiley, 1996). Here, we dem-
onstrate that as a membrane-spanning molecule, the NG2
CSPG, is an amenable target for selective immunoablation
of NG2-expressing glia in vitro, and that this secondary
immunoablation protocol achieves selective destruction of
NG2-glia in situ in cerebellar slice organotypic cultures.
Materials and methods
Animals and tissue
Experiments were performed on cell lines (C6, CTX-TNA2 and
NG108-15) and on cerebellar slices from glial fibrillary acidic protein
(GFAP)–enhanced green fluorescent protein (EGFP) transgenic
mouse line (Nolte et al. 2001), in which the expression of EGFP was
under the control of the human GFAP promoter [line TgN(GFA-
PEGFP) GFEC-FKi] (gift from Frank Kirchhoff, University of Goettin-
gen). Mice aged postnatal day (P)12 were killed humanely in
accordance with the Home Office Animals (Scientific) Act 1986 (UK),
and brains were prepared fresh for cerebellar slice cultures
or immersion fixed in 4% paraformaldehyde (PFA) in phosphate-
buffered saline (PBS) for immunohistochemistry.
Cell lines and culture conditions
C6, CTX-TNA2 and NG108-15 cell lines were obtained from Euro-
pean Collection of Cell Cultures as rat glioma line, transfected astro-
cytes and mouse neuroblastoma9 rat glioma hybrid, respectively.
The F98 cell line was obtained from ATCC-LGC Promochem as a rat
glioma line. CTX-TNA2 and F98 cells were maintained in culture
with Dulbecco’s modified Eagle’s medium (DMEM) (Invitrogen) sup-
plemented with 5% foetal bovine serum (FBS; Invitrogen); C6 cells
with F12 medium (Invitrogen) supplemented with 5% FBS and
L-glutamine (Invitrogen) to 2 mM final concentration; NG108-15 cells
with DMEM supplemented with 5% FBS, L-glutamine to 2 mM final
concentration, 0.6% HAT supplement (Sigma) and with a solution
of penicillin–streptomycin (Penicillin G sodium 10 000 U mL1, strep-
tomycin sulphate 1000 lg mL1) diluted 1 : 100. Cells were cultured
in an incubator at 37 °C with 5% CO2 and 95% air; 75-cm
3 flasks
were used for maintenance of the cell lines, and 24-well plates were
used for experimental purposes. For passaging steps, subconfluent
cultures were digested with 0.25% trypsin/EDTA solution (Invitro-
gen) for 3–5 min, and then resuspended in culture media in a 1 : 10/
1 : 20 ratio.
Cerebellar slice cultures
Cerebellar brain slice cultures were prepared as previously
described, with some modifications (Leoni et al. 2009). Brains from
P11 to P13 mice were rapidly removed and placed in chilled Gey’s
balanced salt solution (Invitrogen), supplemented with 25 mM D-glu-
cose. Cerebellar slices were cut at 300 lm using a McIlwain tissue
chopper, and slices were transferred into six-well culture plates with
1 mL serum-free culture medium per well. Medium was composed
of NeurobasalTM media (Invitrogen) supplemented with B27 supple-
ment (Invitrogen), with 1 mM glutamine (Invitrogen) and 25 mM
D-glucose (Sigma), and a solution of penicillin–streptomycin (Penicil-
lin G sodium 10 000 U mL1, streptomycin sulphate 1000 lg mL1;
Invitrogen) diluted 1 : 500. Slices were cultured at 37 °C in 5% CO2
and 95% air for up to 4 days in vitro, and the culture medium was
replaced every 2 days. Slices were regularly examined and discarded
if contamination occurred. At the end of the experiments, slices
were immersion fixed in 4% PFA for 30 min at room temperature
(RT) for immunohistochemistry.
Immunoablation
Cell cultures were exposed to different concentrations of mouse pri-
mary anti-NG2 antibody (monoclonal from Upstate), alone or in
combination with different concentrations of saporin-conjugated
anti-mouse antibody (Mab-ZAP; Advanced Targeting Systems). Both
Mab-ZAP and primary antibody were diluted in the culture med-
ium, and the secondary conjugate was added first to avoid internal-
ization of the primary antibody before complexing with the
immunotoxin. Control groups included an untreated group (no
primary antibody and no secondary immunotoxin), and single-
treatment groups, where either one of the two antibodies was pre-
sented on its own at different concentrations. For each treatment,
representative pictures of the cells were acquired using a digital
camera adapted on a Nikon Eclipse TS100 microscope, while cell
death was measured using the MTT assay as described below.
Cerebellar slices were treated with two different immunotoxin
combinations: (A) NG2/Mab-ZAP, consisting of mouse monoclonal
anti-NG2 primary antibody (from Upstate, 1 : 1000), with an anti-
mouse secondary antibody linked with the toxin saporin (Mab-ZAP;
from ATS, 5 lg mL1); or (B) NG2/Rab-ZAP, consisting of rabbit poly-
clonal anti-NG2 primary antibody (from Chemicon, 1 : 1000) and
anti-rabbit secondary immunotoxin, Rab-ZAP (from ATS, 5 lg
mL1); control slices (untreated group) were cultured in culture
media. Slices were treated with the anti-NG2-saporin immuno-
cocktail for between 2 and 4 days, and sections were analysed by
immunohistochemistry (see below).
Western blot and reverse transcriptase-polymerase
chain reaction (RT-PCR)
Cell cultures were examined for NG2 expression using Western blot
and RT-PCR. For Western blot, proteins were extracted from the cell
cultures with a lysis buffer composed of 50 mM Tris (pH 7.5), 150 mM
NaCl, 1% Triton X-100, 2 mM EDTA, 2 mM EGTA, 0.5 mM phenylme-
thanesulphonylfluoride, 10 lg mL1 leupeptin, 10 lg mL1 anti-
pain, 1 lg mL1 chimostatin, 1 lg mL1 pepstatin A, 5 mM Na2P2O7,
1 mM Na3VO4 and 50 mM NaF. Lysates were centrifuged and super-
natants were used for the Stanford colorimetric determination of
the total protein content of each sample. Bovine serum albumin
was used to make a standard curve and BioRad reagent was used
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for the protein assay. The remaining supernatants were mixed with
59 Laemmli buffer [312 mM Tris, 0.1 g mL1 sodium dodecyl sul-
phate (SDS), 50% glycerol, 25% mercaptoethanol, 0.125 mg mL1
bromophenol blue] to prepare the loading samples for SDS–poly-
acrylamide gel electrophoresis. The 50 lg of total proteins was run
on a 8% polyacrylamide gel and blotted onto nitrocellulose mem-
branes by semi-dry electroblotting at 1.5 mA cm2. Membranes
were then blocked for 1 h at RT in a blocking solution consisting of
4% skimmed milk powder dissolved in TRIS-buffered saline (TBS;
150 mM NaCl, 10 mM Tris, pH 7.4) added to 0.05% Tween-20 (TTBS).
Membranes were next incubated overnight at 4 °C with a poly-
clonal anti-NG2 antibody (Chemicon), diluted 1 : 2000 in blocking
solution. The membranes were subsequently washed three times
for 5 min in TTBS and then incubated for 1 h at RT in peroxidase-
conjugated goat anti-rabbit IgG (1 : 1000; Sigma). After three fur-
ther washes for 5 min in TTBS, the membranes were finally pro-
cessed with the ECLTM Western blot detection system (GE
Healthcare) and the Hyperfilm-ECL (GE Healthcare) for the detec-
tion of the protein bands. In some cases, clarified homogenates
were digested with chondroitinase ABC in order to cleave the GAG
lateral chain from the native NG2 proteoglycan. Aliquots (150 lL) of
homogenates were added to 5 mU of chondroitinase ABC
(Seikagaku America) and digested for 30 min at 37 °C. Digested
samples were then added to 59 Laemmli buffer as described
above, and stored at 20 °C until use.
For RT-PCR, cell cultures were washed twice in PBS and incubated
for 5 min with 1 mL RNABee (Biogenesis) per well. Each solution
was transferred to Eppendorf tubes, and 100 lL chloroform was
added to each tube, shaken by hand and left on ice for 5 min; sam-
ples were then centrifuged to obtain upper colourless phase con-
taining the RNA, which was then transferred in new Eppendorf
tubes containing 600 lL isopropanol and centrifuged to obtain
pellets. 1 mL of 75% ethanol was added to wash the pellet and
samples were then centrifuged, ethanol was discarded, and pellets
were vacuum-dried for 5 min. The resulting RNA was resuspended
in 35 lL RNA resuspension buffer (10 nM Tris pH 8.0, 10 mM NaCl, 1
mM EDTA) at 65 °C in a water bath. About 5-lL aliquots of each
sample were used to determine the RNA concentration and purity
by determining the A260/A280 ratio with a GeneQuant spectropho-
tometer. The remaining RNA samples were stored at 70 °C until
use for the reverse transcriptase reaction. About 1 lg RNA of each
sample was reverse transcribed into complementary DNA (cDNA) in
a final reaction volume of 20 lL containing 4 lL MgCl2 (25 mM), 2 lL
109 buffer, 2 lL dNTPs (10 mM), 0.5 lL mL1 oligo d(T)15, 0.5 lL
RNase inhibitor and 0.25 lL M-MLV Reverse Transcriptase, RNase H
minus (all reagents were from Promega). The reaction was carried
out at 42 °C for 1 h, followed by 5 min at 95 °C. Negative controls
for the PCR reactions were carried out as described above, but omit-
ting the reverse transcriptase and the RNase inhibitor. cDNA sam-
ples were stored at 20 °C until use. The PCR was carried out in a
final reaction volume of 25 lL containing 2.5 lL cDNA, 1.5 lL MgCl2
(25 mM), 2.25 lL 109 buffer, 1 lL of each forward and reverse prim-
ers (both 2.5 pmol lL1, synthesised by Sigma), 0.125 lL dNTPs (10
mM) and 0.625 U of Taq DNA polymerase. All reagents were from
Promega, except for the primers that were synthesised by Sigma as
follows: 5′-CCTCAGAGCCCTATCTCCACGTAGC-3′ and 5′-CAT-
CACCAAGTAGCCAGCGTTCG-3′ (accession number NM139001). The
PCR reactions were performed in a thermal cycler (GeneAmp 9700;
Applied Biosystem) with an initial denaturating step of 5 min at
94 °C, and 35 cycles of annealing (55 °C), extension (72 °C) and
denaturation (95 °C), 30 s per step. Negative controls of each sample
were also amplified in order to test that genomic DNA was absent
from the cDNA samples. PCR products were run on a 1% agarose
gel together with a 200-bp DNA ladder (Hyper-Ladder I from Bio-
line), and amplified bands were visualised by fluorescence with the
SYBR Safe DNA gel stain 10 0009 concentrated in dimethylsulfide
(Invitrogen), through ultraviolet illumination with UVI/PRO transil-
luminator system (UVIsoft UVIbandWindows Application V10.01).
Immunolabelling
Cell cultures and cerebellar slices were rinsed once with PBS, and
fixed with 4% buffered PFA (pH 7.4) for 30 min at RT. Cells and tis-
sues were washed in PBS, and a blocking stage was performed by
incubation for 1 h at RT in blocking buffer composed of 0.1%
bovine serum albumin plus 10% normal goat serum and, in the case
of brain slices, addition of 1% Triton X-100 in PBS (PBST). Samples
were then incubated overnight at 4 °C with primary antibodies
diluted in blocking buffer: mouse primary anti-NG2 antibody
(monoclonal from Upstate, 1 : 500); rabbit anti-NG2 (either from Dr
Stallcup, 1 : 500, or Chemicon, 1 : 200); chicken anti-GFAP (Chem-
icon, 1 : 200); rabbit anti-calbindin D-28K (Chemicon, 1 : 300). After
three washes in PBST, samples were incubated for 1 h at RT with
the appropriate secondary antibodies conjugated with 488Alexaflu-
or or 567Alexafluor (Molecular Probes, 1 : 500), and in some cases
Hoechst dye (Molecular Probes, 1 : 1000) was used for cell nuclei
counterstaining. For double-immunofluorescence labelling, primary
antibodies of different origin were diluted together in blocking
buffer, and co-dilutions of the appropriate secondary antibodies
were used. After final washes in PBST, samples were mounted on
poly-lysine-coated glass slices with Vectashield mounting media
(Vector Laboratories), and images were acquired using a LSM 5 Pas-
cal Axioskop2 confocal microscope (Zeiss).
MTT cell death assay
Cell cultures were washed once with 19 HBM solution (20 mM
HEPES, 140 mM NaCl, 5 mM KCl, 5 mM NaHCO3, 1.4 mM NaH2PO4)
containing 55 mM glucose and 0.4 mM CaCl2. The cells were then
incubated with 0.5 mL per well of 1.2 mM MTT [Sigma, 3-(4,5-
dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide] for 1 h
at 37 °C, and the MTT solution was subsequently replaced with 300
lL of dimethylsulphoxide to solubilise the resulting formazan prod-
uct. Nearly 200-lL aliquots of each sample were finally transferred
into 96-well plates, and absorbance measured at 480 nm on a PO-
LARstar Optima microplate reader (BMG LABTECH). Data were sta-
tistically analysed with the Origin Lab software. ANOVA was followed
by post-hoc t-test for comparing individual treatment groups.
Cell counts and statistical analysis
Two–four images from random fields of view (FOVs; 4609 460 lm
at 9 20 magnification, or 230 9 230 lm at 9 40 magnification) from
n ≥ 3 cerebellar slices were acquired on a LSM 500 confocal micro-
scope (Zeiss), using LSM Image software (Zeiss). Acquisition parame-
ters of magnification, laser energy source and pinhole aperture
were kept constant between different treatment groups. Numbers
of immunolabelled cells were counted in each FOV, and means
( SEM) calculated for each treatment group. Data were analysed
with GraphPad Prism v3.02 software (GraphPad Software), and
one-way or two-way ANOVA analysis was performed for all the
experimental groups, followed by a post-hoc t-test or Tukey’s test,
as appropriate.
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Results
Efficacy and specificity of NG2-cell immunoablation
in vitro
The immunotoxin system is based on a primary anti-NG2
antibody, and a secondary antibody that is directed against
the primary antibody and to which the toxin saporin is
chemically linked. The primary antibody binds specifically to
the epitope on the cell surface, and provides a vehicle for
the internalisation of the secondary immunotoxin, resulting
in the intracellular release of the toxin saporin and cell
death (Wiley, 1996). To develop a specific immunoablation
system for NG2-expressing cells, it was necessary to first
identify cell lines that strongly expressed NG2 and others
that did not express the proteoglycan. Four cell lines were
selected on the basis that NG2 CSPG is expressed in glioma
cells, but not neurons or astrocytes (Chekenya & Pilkington,
2002), C6 and F98 glioma cell lines, the CTX-TNA2 astrocyte
cell line, and the NG108-15 neural cell line. The four cell
lines were characterised for NG2 expression using immuno-
cytochemistry, Western blot and RT-PCR (Fig. 1). The results
demonstrate that the C6 and F98 glioma cells expressed
high levels of NG2, whereas no NG2 protein was detected
either in the astrocytic CTX-TNA2 cell line or in the neuronal
hybrid NG108-15 cells. Immunocytochemistry clearly demon-
strates that the two glioma cell lines are immunopositive
for NG2 (Fig. 1A,B), whereas CTX-TNA2 and NG108-15 cell
lines are immunonegative (Fig. 1C,D). This was confirmed
by Western blot, where both the 300-kDa core protein and
the 400-kDa native form of NG2 proteoglycan were
detected in C6 and F98 glioma cells (Fig. 1E); enzymatic
digestion of the homogenates with chondroitinase ABC
resulted in the complete conversion of the high molecular
weight form of NG2 into the 300-kDa one, due to the cleav-
age of the GAG lateral chain from the core protein, con-
firming the identity of the protein bands detected. Finally,
differential expression of NG2 was demonstrated at the
mRNA level by RT-PCR (Fig. 1F), amplified products display-
ing the predicted size of 502 bp for NG2 mRNA in both C6
A B
C
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ABC Ch – +
NG108-15 F98 CTX-TNA2
C6
1000
800
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400
200
NG108-15
Mouse
striatum
Mouse
striatum
F98 CTX-TNA2
– + – + – + – +
F
D
Fig. 1 NG2 expression in cell lines. C6, F98,
NG108-15 and CTX-TNA2 cell lines were
tested for NG2 expression using
immunocytochemistry (A–D), Western blot (E)
and RT-PCR (F). (A–D) Cells were
immunolabelled for NG2 (green) with a
mouse monoclonal antibody from Upstate
(1 : 500) and cell nuclei stained with Hoechst
33342 dye (blue). C6 (A) and F98 (B) rat
glioma cells express the NG2 antigen on their
cell surface, whereas the CTX-TNA2 (C) and
NG108-15 (D) cell lines do not express NG2.
Scale bar: 50 lm. (E) Western blotting
revealed protein expression of the NG2 CSPG
in the C6 and F98 cell lines, whereas the
NG108-15 and CTX-TNA2 cell lines were
NG2-negative. The arrows and the
arrowheads indicate the 300-kDa core protein
and the 400-kDa native form of NG2,
respectively, in samples treated (+) with
chondroitinase ABC (ChABC), or prior to
enzymatic digestion (). Treatment with
ChABC determined the complete conversion
of the native form into the 300-kDa form, in
both C6 and F98 cell lines. (F) RT-PCR
confirmed C6 and F98 cell lines express NG2
mRNA, while NG108-15 and CTX-TNA2 cell
lines were negative. A mouse brain extract
was used in both Western blot and RT-PCR as
a positive control, and molecular weight
markers are shown on the left.
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and F98 glioma cell lines, whereas no mRNA was detected
in the astrocytic CTX-TNA2 cells and was barely detectable
in the neuronal hybrid NG108-15 cell line.
On the basis of the expression analyses, the NG2-positive
C6 glioma and NG2-negative CTX-TNA2 astrocyte cell lines
were used to optimise the secondary immunotoxin proto-
col. The results show that compared with controls incuba-
tion with either the primary anti-NG2 antibody alone
(1 : 5000 or 1 : 500 dilutions) or the saporin-conjugated anti-
mouse secondary antibody (Mab-ZAP; 1.0, 0.5 or 1.0
lg mL1) had no effect on cell densities (Fig. 2A–F) or cell
viability, as determined by the MTT assay (Fig. 2G,H; P >
0.05, one-way ANOVA). Having shown that both primary and
secondary antibodies on their own are not toxic for either
C6 or CTX-TNA2 cell lines, we examined the combined
effect of a range of concentrations of the mouse anti-NG2
and Mab-ZAP antibodies presented together (Fig. 3;
Table 1). Cells were examined after 72 h, and in NG2-
expressing C6 glioma cells immunoablation occurred in a
concentration-dependent manner (Fig. 3), whereas the
viability of NG2-negative CTX-TNA2 cells was unaffected by
any of the treatments (Table 1). Thus, only NG2-positive
cells were ablated in the presence of both anti-NG2 anti-
body and the secondary saporin-conjugated secondary
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Fig. 2 Lack of toxicity of either primary or
secondary antibodies in vitro. (A–F) C6 glioma
cells were exposed for 72 h to control culture
media (A), or to either anti-NG2 primary
antibody (a1) alone (B,C) or saporin-conjugate
anti-mouse secondary immunotoxin (ZAP)
alone (D–F), at different concentrations.
Neither of the two antibodies had any toxicity
on the C6 cells, compared with the untreated
control group. Scale bar: 100 lm. (G,H) C6
cells (G) and CTX-TNA2 (H) cells were
exposed for 72 h to either anti-NG2 primary
antibody (a1) or saporin-conjugated anti-
mouse secondary immunotoxin (ZAP), at
different concentrations, and cell viability
measured using the MTT assay. Neither of the
two antibodies had any significant toxicity on
C6 or CTX-TNA2 cells, compared with the
untreated control group. Data are expressed
as mean  SEM.
Table 1 MTT assay for the assessment of the cell viability of CTX-
TNA2 cells after treatment with immunotoxin.
ZAP (lg mL1)
0 0.1 0.5 1.0
NO a1 1.09  0.05 0.91  0.07 0.99  0.08 0.93  0.06
a1 (1 : 500) 0.95  0.05 1.08  0.06 1.07  0.14 0.93  0.04
a1 (1 : 5000) 1.12  0.09 0.92  0.05 0.99  0.05 0.89  0.07
CTX-TNA2 cells were exposed for 72 h to different combinations
of primary anti-NG2 antibody (a1) and secondary immunotoxin
ZAP (0–1.0 lg mL1). Data represent the MTT turnover,
expressed as the MTT product absorbance at 480 nm. None of
the treatments had any significant effect on the cell viability of
the NG2-negative CTX-TNA2 cell line.
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antibody, demonstrating the selectivity and specificity of
the NG2-immunotoxin, with greatest cell death using 1 :
5000 dilution of primary antibody and 0.5–1.0 lg mL1 of
saporin-conjugated secondary antibody, consistent with a
previous study targeting C6 glioma cells using the 192 IgG
primary antibody against the p75NTR (Kohls & Lappi, 2000).
Interestingly, the 1 : 5000 dilution of primary anti-NG2 anti-
body was more effective than the higher concentration
(1 : 500), most likely due to excess primary anti-NG2 compet-
itively inhibiting the binding of conjugated anti-NG2-sapo-
rin to NG2 epitopes and preventing its internalisation into
the cells.
NG2-cell immunoablation in cerebellar slice cultures
The results presented above demonstrated that a combina-
tion of primary antibody against NG2 and secondary immu-
notoxin antibody effectively and selectively killed cultures
of NG2-expressing glia, with no indirect effects of either
antibody on their own. In cerebellar slices, we used both
the mouse anti-NG2 antibody and Mab-ZAP combination
(Fig. 4), and the rabbit polyclonal anti-NG2 antibody with a
secondary anti-rabbit immunotoxin Rab-ZAP (NG2/Rab-ZAP;
Fig. 5). Experiments were performed on cerebellar slices
from P12 to P15 GFAP–EGFP mice to identify astrocytes
(GFAP–EGFP+), in order to confirm the integrity of the slices
and the selectivity of NG2 ablation. After 72 h, slices were
fixed and immunolabelled for NG2 (n ≥ 3 per group). In
controls, NG2-glia and astroglia appeared normal, as previ-
ously described (Leoni et al. 2009), with NG2-glia being uni-
formly distributed across the layers of the cerebellum
intermingled with Bergmann glia with characteristic mor-
phology, with somata in the Purkinje cell layer, and long
primary processes extending through the molecular layer to
the pia (Fig. 4A–C). Notably, there was no loss or disruption
of NG2-glia following treatment with NG2-Mab-ZAP
(Fig. 4D–I), whereas treatment with NG2-Rab-ZAP caused a
marked loss of NG2-glia (Fig. 5). Immunolabelling for NG2
was performed following washout of the immunotoxin,
and the results from NG2-Mab-Zap clearly demonstrate that
NG2 immunostaining per se was not disrupted by incuba-
tion in the cocktail (Fig. 4); NG2-glia exhibited their charac-
teristic morphology of small central somata and radially
extended fine branching processes (Fig. 4G–I), as described
previously (Leoni et al. 2009). The loss of NG2-glia was spe-
cific to treatment with the NG2-Rab-ZAP combination
(Fig. 5), decreasing from 60.8  8.35 cells per FOV in con-
trols and 68.5 7.64 cells per FOV in NG2-Mab-ZAP, to
22.0  3.24 cells per FOV in NG2/RabZAP (Fig. 5D; P < 0.001,
one-way ANOVA and post-hoc Tukey’s key test). In addition,
NG2-Rab-Zap had no effect on immunostaining for NeuN
and synaptophysin (Fig. 6A,B), or on the general distribu-
tion or cell density of EGFP+ astrocytes (Fig. 6C,D); EGFP+
astrocytes were surrounded by degenerating NG2-glia and
debris in immunotoxin-treated slices (Fig. 6E,F). The results
demonstrate that NG2-Rab-ZAP selectively and effectively
ablates NG2-glia.
Following treatment with NG2-Rab-ZAP immunotoxin,
the bulk of NG2 immunostaining appeared as diffuse and
punctate, attributable to debris of dead or dying cells
(Figs 5C and 6E). In addition to this substantial loss of
NG2-glia, compared with controls surviving NG2-glia
appeared degenerative following NG2-RabZAP treatment
(Fig. 7A,B); this was analysed further using morphological
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Fig. 3 Immunoablation of NG2-positive C6 cells. C6 cells were
exposed for 72 h to a combination of Mab-ZAP and primary anti-NG2
antibody (a1) at different concentrations. (A–H) Cell density was clearly
reduced following treatment with NG2-Mab-ZAP. Scale bar: 100 lm.
(I) Cell viability measured by the MTT assay was significantly decreased
following treatment with the combined NG2-Mab-ZAP. For each treat-
ment, n = 4. One-way ANOVA analysis (P < 0.05) was performed over
the three treatment groups. *P < 0.05, **P < 0.01, ***P < 0.001,
post-hoc t-test vs. intra-group controls (0 ZAP).
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criteria to subdivide NG2-glia into: (i) normal process
bearing cells (Fig. 7C); (ii) amoeboid reactive cells (Fig. 7D);
or (iii) severely ‘injured’ cells characterised by fragmented
immunostaining (Fig. 7E). The vast majority of NG2-glia in
control slices (n = 44 cells) were classified as normal (39%)
or amoeboid reactive (61%) cells, and no visibly injured
cells were identified (Fig. 7F). The situation was reversed
following treatment with NG2/Rab-ZAP (Fig. 7G), with 81%
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D
E
F
G
H
I
Fig. 4 Mouse anti-NG2 immunotoxin (NG2/Mab-ZAP) does not affect NG2-glia in cerebellar slice cultures. Cerebellar slices from P13 GFAP–EGFP
mice were cultured for 4 days in vitro, and then fixed and immunolabelled for NG2. Confocal images illustrate the separate channels for NG2
immunolabelling (A,D,G, red), GFP expression (B,F,H, green), and the combined channels (C,F,I). (A–C) Control slices cultured in normal serum-free
medium (CTR). (D–I) Slices exposed for 4 days to a combination of mouse anti-NG2 primary antibody and Mab-ZAP secondary antibody (NG2/
Mab-ZAP). NG2 immunolabelling (A,D,G) and EGFP astroglial reporter protein (B,E,H) show no substantial toxicity of the treatment to either popu-
lation of cells. Arrowheads in (A) indicate NG2-immunopositive vascular pericytes, whereas arrows in (F) indicate NG2-glial cells expressing EGFP.
Asterisks in (G) and (I) illustrate in detail the morphology of NG2-glial cells that were unaffected by the NG2/Mab-ZAP treatment. These NG2-glial
cells were found closely associated with a presumptive Purkinje cell body, indicated by the star in (G–I). GCL, granular cell layer; ML, molecular
layer; PCL, Purkinje cell layer.
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of surviving NG2-glia appearing severely injured and 16%
amoeboid reactive, with very few cells appearing normal
(3%). Note that compared with controls, only 30% of cells
survived the immunotoxin treatment (Fig. 5D), and the vast
majority of these were severely disrupted (Fig. 7G). Further-
more, we have previously reported that NG2-glia begin to
express the astroglial EGFP reporter in cerebellar cultures
(Leoni et al. 2009), and most of the NG2-glial cells surviving
immunotoxin treatment appeared to express the EGFP
reporter (Fig. 8), suggesting these cells may be less suscepti-
ble to immunoablation.
Discussion
In the CNS, the NG2 CSPG is strongly expressed in NG2-glia,
pericytes and certain gliomas (Butt et al. 2002; Chekenya &
Pilkington, 2002; Nishiyama, 2007). One approach to study
cellular function is to use genetic ablation, but NG2 knock-
out mice did not result in the destruction of NG2-glia and
there were only subtle effects on the CNS (Kucharova &
Stallcup, 2010). Hence, we strove to develop an immunotox-
in approach to target the destruction of NG2-glia in situ,
using antibodies directed against the NG2 CSPG in
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Fig. 5 Effective immunoablation of NG2-glia in the cerebellum by the NG2/Rab-ZAP immunotoxin. Representative confocal micrographs of cere-
bellum slices immunolabelled for NG2 after immersion culture for 2 days in vitro, in either control conditions (A), a combination of mouse anti-
NG2 antibody and Mab-ZAP (B), or rabbit anti-NG2 antibody and Rab-ZAP (C). Only NG2-Rab-ZAB caused ablation of NG2-glia. Scale bars: 20 lm.
(D) Cell counts of NG2-immunopositive cells in cerebellum slices expressed as mean number of cells per FOV of 30-lm stack confocal images
acquired at fixed acquisition parameters of magnification, laser source energy, pinhole aperture and stack interval (1 lm). *P < 0.05,
***P < 0.001, one-way ANOVA and post-hoc Tukey’s test.
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combination with a secondary immunotoxin conjugated to
saporin. The primary antibody targets the extracellular
domain of the NG2 CSPG and serves as the vehicle by which
the secondary immunotoxin antibody is internalised into
the NG2-expressing cells. Our results show that this
approach is highly effective for the selective ablation of
NG2-expressing cells in vitro and ex vivo in cerebellar slices.
Immunoablation of NG2-glia was effective after 72 h,
consistent with in vivo studies examining immunoablation
of neurons, which require long-term infusion of immuno-
toxins via cannulae (Wiley et al. 1991; Kwok et al. 1999;
Pizzo et al. 1999). This reflects the time required for the
anti-NG2 primary antibody to bind to the cell surface
epitope, form a tertiary complex with the secondary im-
munotoxin, which must then be internalised for saporin
to be released, and initiate apoptosis (Wiley, 1996; Kohls
et al. 2000). We found the mouse monoclonal anti-NG2-
saporin was very effective at selectively ablating NG2-
expressing C6 glioma cells in vitro, but was totally ineffec-
tive in brain slices. The reason for this is unknown, but pre-
sumably the NG2-Mab-Zap complex was not effectively
internalised in brain slices, demonstrating the importance of
testing multiple antibodies to identify the most efficacious
combinations.
The anti-NG2-saporin immunotoxin effectively
destroyed NG2-glia without adversely affecting astrocyte
or neuronal densities. Furthermore, the vast majority of
surviving NG2-glia appeared severely disrupted, possibly
in the process of dying. In addition, NG2-glia in cerebel-
lar slice cultures begin to express EGFP astroglial reporter
after 48 h (Leoni et al. 2009), and we found that these
cells preferentially survived immunoablation at 72 h.
These GFAP–EGFP+/NG2+ cells appear to display an astro-
cyte–oligodendrocyte (AO) lineage phenotype, which has
been reported by Kirchhoff and colleagues (personal
communication) and is reminiscent of the O-2A cells
described by Raff and colleagues (Raff et al. 1983). NG2-
glia have been reported to generate astrocytes during
development, but do not normally do so in the adult
(Zhu et al. 2008). It seems likely that AO cells generated
A B C
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Fig. 6 Selective immunoablation of NG2-glia. Confocal micrographs of control and immunotoxin-treated (NG2/Rab-ZAP) cerebellum slices. (A,B)
Cerebellar slices obtained from P11 wt mice were cultured for 3 days in vitro in culture media (A) or Rab-ZAP (B) and then immunolabelled for
NeuN (red) and synaptophysin (green), revealing no gross differences between the groups. (C–F) Treatment of P13 cerebellum slices for 3 days in
vitro from GFAP–GFP mice immunolabelled for NG2 (red), with normal medium (C) or NG2/Rab-ZAP immunotoxin (D–F). There were no gross dif-
ferences in the number and distribution of astrocytes in the two treatment groups (C,D), and higher magnification shows viable astrocytes sur-
rounded by NG2-immunopositive debris (E), and NG2-glia with fragmented labelling (F).
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in the cerebellar slice are in the process of losing NG2
and gaining GFAP as they differentiate into astrocytes
(Leoni et al. 2009), and it is possible that downregula-
tion of the NG2 CSPG protects them from the anti-NG2-
saporin immunotoxin.
Our results show it is possible to target NG2-glia in situ,
and this approach holds promise for studying the effects
of NG2-glial cell ablation in vivo. Saporin-conjugated
immunotoxins have been used to effectively target spe-
cific populations of neurons in vivo, such as those directed
against the p75NTR in cholinergic neurons (Wiley et al.
1991, 1995), the dopamine transporter in dopaminergic
neurons (Wiley et al. 2003), and a range of other neuro-
nal targets, including the norepinephrine-synthesising
enzyme dopamine b hydroxylase, NK1 receptor for the
Substance P, the IL-2 receptor, vasopressin and others
(Wiley, 1996). Our findings indicate it would be possible
to use the same approach to examine the functions of
NG2-glia in vivo.
In summary, our study shows that immunoablation is a
feasible option for specifically targeting NG2-glia in situ.
In light of the potential importance of NG2-glia, it is
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Fig. 7 Effect of immunoablation on the morphology of NG2-glia. Cerebellar slices obtained from P12 mice were immersion cultured for 3 days in
vitro and immunolabelled for NG2. (A) NG2-glial cells in control slices had a characteristic stellate processes-bearing morphology. (B) NG2-glial cell
in slice treated with the NG2/Rab-ZAP immunotoxin were severely disrupted and NG2 immunolabelling appeared in ‘clumps’. (C,D) NG2-glia in
slices treated with the NG2/Rab-ZAP immunotoxin were ranked in three morphological classes, corresponding to process-bearing (C), amoeboid
reactive (D), and condensed and fragmented cells (E). (F,G) Pie-chart analysis of the proportions of NG2-glia with the different morphologies
expressed as number of cells per FOV of 30-lm confocal stack.
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perhaps surprising, or at the least disappointing, that NG2
knockout mice have failed to reveal any critical effects in
the CNS (Thallmair et al. 2006; Hossain-Ibrahim et al. 2007;
Kucharova & Stallcup, 2010). However, a comparison can
be made with astrocytes, where knockout of GFAP, which
characterises astrocytes, did not result in a loss of astro-
cytes or disrupt their functions (Pekny et al. 1995). The
immunoablation approach provides a useful experimental
tool for investigating the function of NG2-glia in both
physiological and pathological conditions, such as demye-
lination and degeneration, and could also prove useful in
experiments investigating the influence of oligodendrog-
lial cells on cognitive functions, for example learning and
memory.
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